Here’s what you should know:
1. The collaboration will attempt to discover drugs in Takeda’s key therapeutic areas of interest.
2. Takeda will provide protein crystal structures to Schrödinger for use in its in silico technology platform.
3. Schrödinger will cover all discovery costs, providing Takeda with rights to license the programs from Schrödinger.
4. Takeda will pay up to $170 million per program as well as potential royalties.
More articles on improving performance:
ASC leader to know: Stephanie Harvey of the Association of Wisconsin Surgery Centers
The California ‘surprise medical bill’ impacting surgery centers: 4 things to know
New York firm buys ASC operator: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
